New drug therapies for the pediatric rheumatic diseases

Current Opinion in Rheumatology

Volumn 13, Issue 5, 2001, Pages 410-414

  Bloom, Bradley J ^a,b  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

CHILD; DRUG RESEARCH; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCER; VASCULITIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0034805941     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200109000-00012     Document Type: Review

References (41)

1. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
2. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
3. Rofecoxib, a specific inhibitor of cyclooxygenaee 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
4. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
5. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gaetroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
6. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase-2 inhibitors: A report of four cases
7. Are selective COX-2 inhibitors nephrotoxic?
8. Acute renal failure associated with rofecoxib
9. Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis
10. Acute pancreatitis associated with celecoxib
11. Celecoxib-induced acute pancreatitis and hepatitis: A case report
12. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized trials of leflunomide in patients with active rheumatoid arthritis
13. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
14. Efficacy of mycophenylate mofetil in patients with diffuse proliferative lupus nephritis
15. Effect of adding Mycophenolate mofetil in pediatric renal transplant recipients with chronic cyclosporine nephrotoxicity
16. Conversion from azathioprine to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection
17. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children
18. The short-term safety and efficacy of mycophenolate (Cell Cept) in treatment of children with pediatric rheumatic diseases
19. Use of mycophenolate mofetil therapy in childhood SLE
20. Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular-course JRA
21. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis
22. Treatment of systemic JIA with etanercept: Results of a survey
23. Use of etanercept in the treatment of macrophage activation syndrome
24. Efficacy of etanercept in refractory juvenile spondyloarthropathy
25. Experience with etanercept in chronic juvenile dermatomyositis: Preliminary results
26. Long-term follow-up of patients treated with infliximab in clinical trials
27. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis
28. Infliximab in the treatment of persistently active juvenile idiopathic (chronic) arthritis: A short-term pilot study
29. Infliximab vs. etanercept in the treatment of severe juvenile chronic arthritis
30. Tumor necrosis factor-α blockers and the induction of anti-DNA autoantibodies
31. Assessment of autoantibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-α: Findings in open-label and randomized placebo-controlled trials
32. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
33. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
34. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
35. The effects of interferon beta treatment on arthritis
36. Treatment of refractory juvenile rheumatoid arthritis
37. Sulfasalazine for the management of JRA
38. A subgroup-specific evaluation of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis
39. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis
40. Intravenous immunoglobulin therapy for juvenile dermatomyositis: Efficacy and safety
41. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus